
Noah Ojonugwa Agada MD MPH, FAAP
Asthma & Allergic Conditions, Pediatric Asthma & Allergic Conditions
Physician
Join to view full profile
4601 W Market StSte BGreensboro, NC 27407
Phone+1 336-733-9016
Fax+1 336-500-8335
Dr. Agada is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Noah Agada is an Allergy and Immunology specialist based in Carmel, IN, with subspecialties in Asthma and Allergic Conditions, as well as Pediatric Asthma and Allergic Conditions. He completed a fellowship in Allergy and Immunology at Duke University Hospital and a residency in Pediatrics at Wright State University. He holds an MPH in Public Health from Johns Hopkins University and an MSc in Chemical Pathology from the University of Ibadan.
Dr. Agada currently practices as an Allergist/Immunologist at Allergy & Asthma Clinics, Greensboro,NC. His published work includes research on clinical efficacy improvements in ulcerative colitis and safety studies related to psoriasis treatments, which have been cited in various journals.
Education & Training
Duke University HospitalFellowship, Allergy and Immunology, 2013 - 2015
Wright State UniversityResidency, Pediatrics, 2010 - 2013
Johns Hopkins UniversityMPH, Public Health, 2008 - 2009
University of IbadanMSc, Chemical Pathology, 2000 - 2002
University of Jos Faculty of MedicineClass of 1990
Certifications & Licensure
DC State Medical License 2024 - 2028
IN State Medical License 2015 - 2027
NC State Medical License 2013 - 2027
OH State Medical License 2010 - 2013
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- 1 citationsInfusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease.Paul Ardayfio, Garrett R Mullins, Rashna Khanna, Jennifer A Zimmer, Hong Wang
Alzheimer's & Dementia. 2026-03-08 - 7 citationsChanges in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.Marla C Dubinsky, Vipul Jairath, Brian G Feagan, April N Naegeli, Jay Tuttle
BMJ Open Gastroenterology. 2023-03-01 - 4 citationsCase Report: Nontuberculous mycobacterial infections in children with complete DiGeorge anomaly.Elizabeth Daly Hicks, Noah O Agada, Tyler R Yates, Matthew S Kelly, Jonathan S Tam
Frontiers in Immunology. 2023-01-01
Journal Articles
- Long‐Term Safety Profile of Ixekizumab in Patients with Moderate‐to‐Severe Plaque Psoriasis: An Integrated Analysis from 11 Clinical TrialsA B Kimball, N Agada, Journal of The European Academy of Dermatology and Venereology
Professional Memberships
- Member
- Member
- Member
External Links
- Carmel Allergyhttp://www.carmelallergy.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









